Aller au contenu principal
Profil bibliographique

Gustavo Caruso

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

43Publications signalées
172Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Blood Pressure and Hypertension StudiesObstructive Sleep Apnea ResearchHormonal Regulation and HypertensionSodium Intake and HealthDiabetes Treatment and Management

Les publications récentes

2024 conference-abstract OpenAlex

OBSTRUCTIVE SLEEP APNEA AND AUTONOMIC DYSFUNCTION

Abel Berger, Gustavo Caruso, Martín Sívori, Javier Iriarte et autres

Objective: To investigate 1) the relationship between sympathetic nervous system activity and the Apnea Hypopnea Index (AHI), a simplified outpatient OSA identifier. Design and method: A cross-sectional, observational analytical study including patients with suspected OSA were invited to participate. The office blood …

ar (code pays fourni par la source)

0 citations Journal of Hypertension
2022 article OpenAlex

Registro Argentino de Medición de la Presión Arterial en Consultorio. Estudio RAMPAC

Diego Francisco Márquez, Maria E. Garzon, Nicolas Federico Renna, Marcos BaronI et autres

La hipertensión es el factor de riesgo más importante para la muerte cardiovascular a nivel mundial. En Argentina cerca del 44% de las personas desconocen ser hipertensos, y posiblemente sea debido a que no se les mide de la presión arterial (PA) …

ar, us (code pays fourni par la source)

0 citations Hipertensión y Riesgo Vascular
Accès ouvert 2021 article OpenAlex

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

Kieran F. Docherty, Pardeep S. Jhund, Brian Lee Claggett, João Pedro Ferreira et autres

Importance: Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results …

gb, us, fr, se, dk, au, ar, pl (code pays fourni par la source)

18 citations JAMA Cardiology
Accès ouvert 2020 article OpenAlex

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson, David L. DeMets et autres

OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN …

gb, se, us, dk, au, ar (code pays fourni par la source)

44 citations Diabetes Care
2016 book-review OpenAlex

[PP.34.06] SEVERE SNORES WITHOUT APNEA AND UNDERESTIMATED HIGH BLOOD PRESSURE

Gustavo Caruso, Dania Bacardi Fernández, Manuel Gorostidi Pérez, Marcela Smurra et autres

Objective: Snoring is the main manifestation of Obstructive Sleep Apnea Syndrome (OSAS) Hypertension (HPB) occurring in this subject is more likely to be associated with alterations in day to night BP changes. It described an association between snoring and HBP, but it …

ar (code pays fourni par la source)

0 citations Journal of Hypertension
Accès ouvert 2015 article OpenAlex

Long-term disability after lacunar stroke

Mandip S. Dhamoon, Leslie A. McClure, Carole L. White, Kamakshi Lakshminarayan et autres

OBJECTIVES: To determine whether vascular and demographic factors predict worsening disability up to 8 years after lacunar stroke. METHODS: SPS3 (Secondary Prevention of Small Subcortical Strokes) was a clinical trial in lacunar stroke patients with annual assessment of disability using the Older …

ca, us (code pays fourni par la source)

39 citations Neurology
Accès ouvert 2012 article OpenAlex

Monitoreo ambulatorio de presión arterial (mapa) y duración del efecto antihipertensivo: un estudio con una nueva forma farmacéutica de losartán de liberación sostenida (CRONOS)

Mario Bendersky, Luis Augusto Juncos, Gabriel Darío Waisman, Daniel Leonardo Piskorz et autres

Antihypertensive drugs action should last at least 24 h in order to enhance adherence, with positive impact on CV morbimortality. ABPM allow us to evaluate duration of action of drugs, against placebo, using Trough:Peak Ratio, antihypertensive effect in the last 4 h …

us, ar, ch (code pays fourni par la source)

1 citation Revista de la Facultad de Ciencias Médicas de Córdoba
2012 conference-abstract OpenAlex

1007 EVALUATION OF ANTIHYPERTENSIVE EFFECT WITH ABPM OF A NEW PHARMACEUTICAL FORM OF LOSARTAN

Mario Bendersky, Luis Augusto Juncos, Ricardo López-Santi, Oscar R. Montaña et autres

Background: Previous studies have demonstrated that Losartan does not have 24-h action. Losartan Cronos is a new pharmaceutical form containing in a single tablet 50 mg of Losartan immediate release and 50 mg extended release. Objectives: Assess Losartan Cronos efficacy and duration …

cz, es, in, ar, br (code pays fourni par la source)

0 citations Journal of Hypertension

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.